Laboratory Corporation of America Holdings, also known as Labcorp, is a leading global life sciences company that is involved in deep scientific research and forward-thinking advancements in the medical field. The company is listed on the New York Stock Exchange under the ticker symbol 'LH'. Based in Burlington, North Carolina, Labcorp was established in 1978.
Labcorp’s mission is to improve health and improve lives. It caters to a range of clients – including physicians, hospitals, pharmaceutical and biotechnology companies, and patients directly. The company provides comprehensive clinical laboratory and end-to-end drug development services. Its areas of expertise are wide-ranging and include diagnostics, drug development, genomics, proteomics, and digital solutions.
Its diagnostics unit operates one of the largest clinical laboratory networks in the world, with more than 30 primary labs across the United States. It provides an array of routine and specialty testing services, such as allergy testing, genetic testing, oncology testing and more, allowing physicians to make informed and timely decisions.
Meanwhile, Labcorp's drug development unit, known as Covance, supports drug development and commercialization from preclinical to post-market. It offers solutions that generate higher quality and safer therapies to speed patient access to treatments.
Labcorp maintains a dedicated workforce of over 70,000 employees worldwide. The company’s achievements over the years have made a significant impact on the medical and scientific communities. Labcorp plays a pivotal role in advancing personalized medicine, transforming clinical trials, and improving patient care.
In 2020, Labcorp rose to the forefront of the global fight against the COVID-19 pandemic by providing COVID-19 testing solutions and playing a critical role in accelerating vaccine and treatment development. This further solidified the company's commitment to improving health and saving lives.
The Company maintains high ethical standards and is committed to doing business the right way by focusing on corporate responsibility. It aims to create a positive impact on society through environmental sustainability, community involvement, and responsible business practices.
In conclusion, Laboratory Corp of America Holdings is an indispensable part of the global health landscape. As they continue to innovate and support breakthroughs in the medical field, their work will remain essential in our collective effort to improve healthcare outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Federal health advisers have endorsed Grail Inc.'s Galleri blood test, which can detect signs of over 50 types of cancer in healthy individuals, though they cautioned about its limitations. The advisory panel voted that the test offers potential benefits despite concerns about false positives or negatives, and noted that more research is needed to prove its effectiveness for early detection. If the FDA approves it, widespread U.S. adoption could follow, making it more accessible through insurance coverage, but it should be used in conjunction with, not as a replacement for, existing cancer screenings.
An FDA advisory committee has recommended approval for Grail's Galleri blood test, designed to detect various cancers early, despite concerns from doctors regarding its efficacy. Although hundreds of thousands have used the test, there's no data from randomized controlled trials showing it reduces cancer deaths, and a large trial in the U.K. failed to show a reduction in advanced cancer diagnoses. The test currently costs $949 out-of-pocket, but successful lobbying could lead to Medicare coverage starting in 2028 if FDA approval is granted.
A federal health advisory panel has endorsed Grail Inc.'s Galleri blood test for detecting signs of various cancers in healthy individuals, despite acknowledging uncertainties about its effectiveness and the need for further study. The panel voted 7-2 that the benefits outweigh the risks, paving the way for potential widespread adoption if the FDA agrees, though they stressed it should supplement, not replace, existing cancer screenings.
An FDA advisory panel has recommended approval for Grail's Galleri blood test, the first multi-cancer detection blood test, for individuals aged 50 and over. While the test can detect up to 50 forms of cancer, concerns were raised about its effectiveness in early detection and potential for false senses of security. The panel's recommendation includes caveats for marketing materials, emphasizing that the test should supplement, not replace, standard cancer screenings.
Labcorp Holdings (NYSE: LH) stock dropped 3.3% after the Centers for Medicare & Medicaid Services (CMS) announced a 15% reduction in reimbursement rates for lab costs, effective January 1, 2027. This change is expected to save taxpayers $1 billion annually but will impact Labcorp's revenue. The company's 10-K filing had previously identified such reductions as a key risk, noting that CMS revenue constitutes about 8% of its total.
/Quest%20Diagnostics%20is%20an%20American%20clinical%20laboratory_By%20JHVEPhoto.jpeg)
Quest Diagnostics (DGX) has significantly outperformed the Nasdaq Composite ($NASX) over the past three months, year-to-date, and over the last 52 weeks, driven by growth in core routine testing and advanced diagnostics. The company's strategic acquisitions, partnerships, and consumer-initiated testing have further strengthened its market position. Analysts maintain a "Moderate Buy" rating for DGX, with a modest upside potential from current price levels.